drugset / Trial / NCT03464682
Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia
RandomizedParallel-groupDouble-blindTreatment
Summary
To determine the efficacy of the HS-25 (10mg or 20mg) or in combination with Atorvastatin (10mg)in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in adults with primary hypercholesterolemia; To determine the safety of HS-25 (10mg or 20mg) or in combination with Atorvastatin (10mg)in subjects with LDL-C after a 40-week period of treament.
Timeline
- Start
- 2015-02-28
- Primary completion
- 2018-12-28
- Completion
- 2019-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 10 mg | Oral |
| Subject | HYZETIMIBE | Small molecule | 10 mg | Oral |
| Subject | HYZETIMIBE | Small molecule | 20 mg | Oral |